Lv11
70 积分 2023-02-05 加入
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
9天前
已完结
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
10天前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
10天前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
14天前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
20天前
已完结
Spatially resolved single-cell atlas reveals the macroevolutionary trajectory of animal hearts
1个月前
已完结
Longitudinal genomic analysis of five cases of recurrent thymomas
1个月前
已关闭
Longitudinal genomic analysis of five cases of recurrent thymomas
1个月前
已关闭
Brief Report: Low Delta-Like Ligand 3 Expression and T-Cell Exhaustion Drive Resistance to Tarlatamab Combined With Anti–Programmed Cell Death Protein 1 in SCLC
1个月前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
